These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 24338340)
1. How do I recommend extended adjuvant hormonal therapy? Mehta A; Carpenter JT Curr Treat Options Oncol; 2014 Mar; 15(1):55-62. PubMed ID: 24338340 [TBL] [Abstract][Full Text] [Related]
2. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. Conte B; Poggio F; Del Mastro L Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603 [TBL] [Abstract][Full Text] [Related]
3. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. Carlson RW; Hudis CA; Pritchard KI; ; ; J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447 [TBL] [Abstract][Full Text] [Related]
5. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Perez EA Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211 [TBL] [Abstract][Full Text] [Related]
6. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Carlson RW; Henderson IC Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531 [TBL] [Abstract][Full Text] [Related]
7. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595 [TBL] [Abstract][Full Text] [Related]
8. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Gradishar WJ Oncology; 2005; 69(1):1-9. PubMed ID: 16088229 [TBL] [Abstract][Full Text] [Related]
9. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808 [TBL] [Abstract][Full Text] [Related]
10. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Mouridsen HT Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085 [TBL] [Abstract][Full Text] [Related]
11. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082 [TBL] [Abstract][Full Text] [Related]
12. Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. van Hellemond IEG; Geurts SME; Tjan-Heijnen VCG Curr Treat Options Oncol; 2018 Apr; 19(5):26. PubMed ID: 29704066 [TBL] [Abstract][Full Text] [Related]
13. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Burstein HJ; Prestrud AA; Seidenfeld J; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Malin J; Mamounas EP; Rowden D; Solky AJ; Sowers MR; Stearns V; Winer EP; Somerfield MR; Griggs JJ; J Clin Oncol; 2010 Aug; 28(23):3784-96. PubMed ID: 20625130 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy for breast cancer. Rao RD; Cobleigh MA Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539 [TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy for early breast cancer. Hussain SA; Williams S; Stevens A; Rea DW Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know? Chung CT; Carlson RW Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435 [TBL] [Abstract][Full Text] [Related]
17. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen. Carpenter R Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017 [TBL] [Abstract][Full Text] [Related]
18. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study. Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. Smith IE; Dowsett M; Yap YS; Walsh G; Lønning PE; Santen RJ; Hayes D J Clin Oncol; 2006 Jun; 24(16):2444-7. PubMed ID: 16735701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]